Erratum: CCR2 modulates inflammatory and metabolic effects of high-fat feeding (Journal of Clinical Investigation (2006) 116, (115-124) DOI:10.1172/JCI24335));CCR2 modulates inflammatory and metabolic effects of high-fat feeding

Journal of Clinical Investigation

Volumn 116, Issue 1, 2006, Pages 115-124

  Weisberg, Stuart P ^a   Hunter, Deborah ^b   Huber, Reid ^b   Lemieux, Jacob ^a   Slaymaker, Sarah ^c   Vaddi, Kris ^b   Charo, Israel ^c   Leibel, Rudolph L ^a   Ferrante Jr , Anthony W ^a,d  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Experimental Station   (United States)

^c GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; FAT; GLUCOSE; INCB 3344; INSULIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CONTROLLED STUDY; FAT INTAKE; FATTY LIVER; FOOD INTAKE; GENOTYPE; GLUCOSE HOMEOSTASIS; INFLAMMATION; INSULIN SENSITIVITY; LIPID DIET; MACROPHAGE; METABOLIC REGULATION; METABOLISM; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 31044456529     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24335C1     Document Type: Erratum

References (49)

1. Berg, A.H., and Scherer, P.E. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96:939-949.
2. Browning, J.D., and Horton, J.D. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114:147-152. doi:10.1172/ JCI200422422.
3. Wellen, K.E., and Hotamisligil, G.S. 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115:1111-1119. doi:10.1172/JCI200525102.
4. Pickup, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 27:813-823.
5. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87-91.
6. Bastard, J.P., et al. 1999. Evidence for a link between adipose tissue interleukin-6 content and serum Creactive protein concentrations in obese subjects. Circulation. 99:2221-2222.
7. Fried, S.K., Bunkin, D.A., and Greenberg, A.S. 1998. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83:847-850.
8. Weisberg, S.P., et al. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112:1796-1808. doi:10.1172/JCI200319246.
9. Lin, H.Z., et al. 2000. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6:998-1003.
10. Cai, D., et al. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11:183-190.
11. Brodmerkel, C.M., et al. 2005 Discovery and pharmacological characterization of a novel rodent active CCR2 antagonist, INCB3344. J. Immunol. 175:5370-5378.
12. Skurk, T., and Hauner, H. 2004. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28:1357-1364.
13. Hirosumi, J., et al. 2002. A central role for JNK in obesity and insulin resistance. Nature. 420:333-336.
14. Yuan, M., et al. 2001. Reversal of obesity- and dietinduced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 293:1673-1677.
15. Arkan, M.C., et al. 2005. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11:191-198.
16. xu, H., et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821-1830. doi:10.1172/JCI200319451.
17. Curat, C.A., et al. 2004. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes. 53:1285-1292.
18. Takahashi, K., et al. 2003. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J. Biol. Chem. 278:46654-46660.
19. Mohanty, P., et al. 2004. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89:2728-2735.
20. Bruun, J.M., Lihn, A.S., Pedersen, S.B., and Richelsen, B. 2005. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab. 90:2282-2289.
21. Sartipy, P., and Loskutoff, D.J. 2003. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 100:7265-7270.
22. Kurihara, T., and Bravo, R. 1996. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J. Biol. Chem. 271:11603-11607.
23. McQuibban, G.A., et al. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 289:1202-1206.
24. Charo, I.F., and Peters, W. 2003. Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation. 10:259-264.
25. Di Gregorio, G.B., et al. 2005. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 54:2305-2313.
26. Christiansen, T., Richelsen, B., and Bruun, J.M. 2005. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. Relat. Metab. Disord. 29:146-150.
27. Boring, L., et al. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552-2561.
28. Kurihara, T., Warr, G., Loy, J., and Bravo, R. 1997. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186:1757-1762.
29. Nanji, A.A. 2004. Animal models of nonalcoholic fatty liver disease and steatohepatitis. Clin. Liver Dis. 8:559-574, ix.
30. Wellen, K.E., and Hotamisligil, G.S. 2003. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112:1785-1788. doi:10.1172/ JCI200320514.
31. Soukas, A., Cohen, P., Socci, N.D., and Friedman, J.M. 2000. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 14:963-980.
32. Nadler, S.T., et al. 2000. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 97:11371-11376.
33. Wilson-Fritch, L., et al. 2004. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin. Invest. 114:1281-1289. doi:10.1172/JCI200421752.
34. Pavlidis, P., Weston, J., Cai, J., and Noble, W.S. 2002. Learning gene functional classifications from multiple data types. J. Comput. Biol. 9:401-411.
35. Statnick, M.A., et al. 2000. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int. J. Exp. Diabetes Res. 1:81-88.
36. Kern, P.A., Di Gregorio, G.B., Lu, T., Rassouli, N., and Ranganathan, G. 2003. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factoralpha expression. Diabetes. 52:1779-1785.
37. Vendrell, J., et al. 2004. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes. Res. 12:962-971.
38. Dandona, P., et al. 1998. Tumor necrosis factoralpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83:2907-2910.
39. Lehrke, M., et al. 2004. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 1:e45.
40. Reilly, M.P., et al. 2005. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 111:932-939.
41. Ginsberg, H.N. 1991. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care. 14:839-855.
42. Ginsberg, H.N. 2000. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106:453-458.
43. Ross, S.E., et al. 2002. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver x receptor alpha in adipocyte metabolism. Mol. Cell. Biol. 22:5989-5999.
44. Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., and Bahouth, S.W. 2004. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 145:2273-2282.
45. Fain, J.N., Cheema, P.S., Bahouth, S.W., and Lloyd Hiler, M. 2003. Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300:674-678.
46. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
47. Pavlidis, P., and Noble, W.S. 2001. Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol. 2:research0042.1- research0042.15.
48. Cecchini, M.G., et al. 1994. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development. 120:1357-1372.
49. Vandesompele, J., et al. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3:research0034.1-research0034.11.